









Markets
/
Stocks
/
nasdaq-cdio
/

Cardio Diagnostics Holdings Inc

CDIO

1.290USD

+0.240+22.86%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.28MMarket Cap

LossP/E TTM



Cardio Diagnostics Holdings Inc

1.290

+0.240+22.86%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cardio Diagnostics Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

Cardio Diagnostics Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 232 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 60.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cardio Diagnostics Holdings Inc's Score

Industry at a Glance

Industry Ranking

232 / 392

Overall Ranking

497 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Cardio Diagnostics Holdings Inc Highlights

StrengthsRisks

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 3572.63% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 34.89K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 34.89K.

Overvalued

The company’s latest PE is -0.40, at a high 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 24.12K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

60.000

Target Price

+1227.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Cardio Diagnostics Holdings Inc is 6.53, ranking 243 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.85K, representing a year-over-year decrease of 56.61%, while its net profit experienced a year-over-year decrease of 21.38%.

Score

Industry at a Glance

Previous score

6.53

Change



Financials

9.94

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.41

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.38

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cardio Diagnostics Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Cardio Diagnostics Holdings Inc is 5.85, ranking 360 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.40, which is -72.15% below the recent high of -0.11 and -119890.53% above the recent low of -483.80.

Score

Industry at a Glance

Previous score

5.85

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 232/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Cardio Diagnostics Holdings Inc. The Biotechnology & Medical Research industry's average is 8.05. The average price target is 60.00, with a high of 60.00 and a low of 60.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Cardio Diagnostics Holdings Inc is 4.06, ranking 354 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.10 and the support level at 0.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.06

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.038

Sell

RSI(14)

31.374

Neutral

STOCH(KDJ)(9,3,3)

19.150

Buy

ATR(14)

0.186

High Vlolatility

CCI(14)

-110.705

Sell

Williams %R

69.668

Sell

TRIX(12,20)

-2.624

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.274

Buy

MA10

1.491

Sell

MA20

1.682

Sell

MA50

2.556

Sell

MA100

3.243

Sell

MA200

4.170

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Cardio Diagnostics Holdings Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 6.22%, representing a quarter-over-quarter decrease of 7.23%. The largest institutional shareholder is The Vanguard, holding a total of 24.12K shares, representing 1.32% of shares outstanding, with 84.92% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Dogan (Meeshanthini)

55.18K

Bd Holding, Inc

52.88K

BlackRock Institutional Trust Company, N.A.

35.57K

The Vanguard Group, Inc.

Star Investors

24.12K

+90.22%

Citadel Advisors LLC

19.52K

DRW Securities, LLC

18.16K

Geode Capital Management, L.L.C.

15.10K

+12.97%

Dogan (Timur)

4.28K

Hosseinion (Warren)

3.87K

+0.03%

Philibert (Robert)

3.25K

+0.03%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cardio Diagnostics Holdings Inc is 1.58, ranking 302 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.93. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.